Search Results - "Galve Calvo, E."

First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN by Martínez-Jañez, N., Ezquerra, M. Bellet, Manso Sanchez, L. M., Carrasco, F. Henao, Torres, A. Anton, Morales, S., Ortega, P. Tolosa, Gil, V. L. Obadia, Sampedro, T., Conejero, R. Andrés, Calvo-Martinez, L., Galve-Calvo, E., López, R., de la Pena, F. Ayala, Lopez-Tarruella, S., de Araguiz, B. A. Hernando Fernandez, Ruiz, L. Boronat, Cardenas, T. Martos, Chacon, J. I., Antón, F. Moreno

“…Purpose To evaluate the efficacy and safety of first-line therapy with palbociclib in a Spanish cohort treated after palbociclib approval. Methods PALBOSPAIN…”
Get full text

Surgery of the primary tumor for de novo metastatic breast cancer: The controversy continues by López de San Vicente, B., Galve Calvo, E., Zumarraga, A., Pikab ea, F., Arango Arteaga, J.F., López Santillan, M., Figaredo, C., Sala Gonzalez, M.A., Nuño Escolastico, M., Novas Vidal, P., Legaspi, J., Martinez del Prado, P.

Get full text

Consensus of the Spanish society of laboratory medicine and the Spanish society of medical oncology on the methodology and criteria for evaluation of circulating tumour markers in breast cancer by Ayala de la Peña, F., Ortiz-Muñoz, B., Quintanar-Verdúguez, T., Santotoribio, J. D., de la Cruz, S., Trapé-Pujol, J., Galve-Calvo, E., Augé-Fradera, J. M., García-Gómez, J., González-Hernández, Á.

“…The measurement of circulating tumour markers (TMs) for the diagnosis or monitoring of breast cancer has sometimes been considered of limited utility. In…”
Get full text

Management of patients with metastatic breast cancer by Cruz Jurado, Josefina, Richart Aznar, Paula, García Mata, Jesus, Fernández Martínez, Roberto, Peláez Fernández, Ignacio, Sampedro Gimeno, Teresa, Galve Calvo, Elena, Murillo Jaso, Laura, Polo Marqués, Eduardo, García Palomo, Andrés

“…Hormone treatment is one of the key strategies in the management of metastatic breast cancer. Hormone treatment is one of the key strategies in the management…”
Get full text

236P Predicting Oncotype DX recurrence scores using clinicopathologic features: Tennessee University Nomogram: An external validation by Pikabea Díaz, F., Galve Calvo, E., Zumarraga, A., Figaredo Bejarano, C., Sala Gonzalez, M.A., Lopez Santillan, M., Lopez De San Vicente, B., Casado, P., Martinez del Prado, M.P.

Get full text

EE528 Analysis of Non-Pharmacological Cost Savings Derived from the Use of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in Patients with HER2-Positive Breast Cancer in Spain by Calleja, T., Galve-Calvo, E., Gómez Agudo, E., Llaguno, J.L., Martin Rufo, M., Arroyo, I., Lagunar Ruiz, J., Lorés, M., Monzón, M., Saura, C.

Get full text

387MO First results of the SOLTI-1903 HOPE's patient-centric molecular screening program in advanced breast cancer by Pascual, T., Solis, E. Segui, Olivera-Salguero, R., Cejalvo, J.M., Oliveira, M., Ortega, P. Tolosa, Losada, M.J. Vidal, Malumbres, M., Gavilá-Gregori, J., Manich, C. Saura, Simon, S. Pernas, Vila, M. Margeli, Ciruelos, E.M., Galve-Calvo, E., Galván, P., Sanfeliu Torres, E., Olmos, R., Forns, M., Fernandez Tejerina, A. Casas, Prat, A.

Get full text

PO-84 Incidence of venous thromboembolism and Khorana score in patients with sarcoma: a retrospective study in a single institution by Figaredo Berjano, C., Zumárraga Cuesta, A., Sala Gónzalez, M.A., López de San Vicente Hernández, A., Nuño Escolástico, M., Galve Calvo, E., Martínez del Prado, M.P.

Get full text

PO-14: Real-world data: incidence of venous thromboembolism recurrence and bleeding among cancer patients by Silva-Cardenas, D.C., Pikabea-Diaz, F., Zumarraga-Cuesta, A., Lopez-Santillan, M., Figaredo-Berjano, C., Loaiza-Jaramillo, P.L., Casado-Cuesta, P., Temiño-Frances, M., Lopez-de-San-Vicente-Hernandez, B., Novo-Sukia, E., Legaspi-Folgueira, J., Barcelo-Galindez, J.R., Sande-Sardina, L., Nuno-Escolastico, M., Abad-Villar, M.T., Sala-Gonzalez, M.A., Galve-Calvo, E., Martinez-del-Prado, M.P.

Get full text

359PSurgery of the primary tumor for de novo metastatic breast cancer: The controversy continues by López de San Vicente, B, Galve Calvo, E, Zumarraga, A, Pikab ea, F, Arango Arteaga, J F, López Santillan, M, Figaredo, C, Sala Gonzalez, M A, Nuño Escolastico, M, Novas Vidal, P, Legaspi, J, Martinez del Prado, P

Get full text

213P Real-world clinical outcomes associated with first-line palbociclib and aromatase inhibitor therapy among patients with HR+/HER2- advanced breast cancer in Europe by Oikonomidou, O., Galve-Calvo, E., Wöckel, A., Parikh, R., Hitchens, A., Chen, C., Gauthier, E., Li, B., Ansquer, V. Derrien, Frugier, G., Jimenez, M., Davis, K., Broughton, E.

Get full text

116P Time and motion randomised study of a subcutaneous (SC) pertuzumab and trastuzumab fixed-dose combination (PH FDC) for the treatment of HER2-positive early breast cancer (HER2 EBC): PHaTiMa by González-Santiago, S., López-Miranda, E., Escrivá-De-Romaní, S., Jiménez-Rodríguez, B., Antolín-Novoa, S., González-Cortijo, L., Fernández-Morales, L.A., Galve-Calvo, E., Martorell, A. Perello, Arroyo-Rivera, I., García-Bernáldez, C., Lagunar-Ruiz, J., Gavilá-Gregori, J.

Get full text

Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2- advanced or metastatic breast cancer in Spain by Galve-Calvo, Elena, González-Haba, Eva, Gostkorzewicz, Joana, Martínez, Irene, Pérez-Mitru, Alejandro

“…The aim of this study was to evaluate the cost-effectiveness of ribociclib compared to palbociclib, both in combination with letrozole, in the first-line…”
Get full text

1101 Multimodality imaging in the assessment of pericardial malign disease by Codina, M, Ramirez-Escudero Ugalde, G, Manzanal Rey, A, Garcia Ibarrondo, N, Cisneros Carpio, S, Lambarri Izaguirre, A, Candina Urizar, R, Ugedo Alzaga, K, Castellanos Alcalde, M, Rodriguez Martinez, M, Sande Sardina, L, Galve Calvo, E, Arcocha Torres, M F, Ormaetxe Merodio, J, Ruiz Gomez, L

“…Abstract Metastases to the heart and pericardium are discovered at autopsy in 10%–12% of all patients with malignancies. The most common primary tumor…”
Get full text

Retrospective observational study to evaluate the use of halaven plus trastuzumab for the treatment of HER2(+) metastatic breast cancer (MBC) in Spain: HALATRUST study by Echarri González, M.J., Ayala de la Peña, F., Márquez Vázquez, R., García-Saenz, J.A., Galve Calvo, E., Illarramendi Mañas, J.J., Millastre Bocos, E., Margelí Vila, M., Sánchez Rovira, P., Chacón López-Muñiz, J.I., Cerezuela Fuentes, P., Andrés Conejero, R., Cerrato Crespan, L., Marrodán Ciordia, I., Ocana Fernandez, A., Álvarez López, I., Alés Martínez, J.E., Palomar Abad, L., Orcajo Rincon, L., Rodríguez-Villanueva, J.

Get full text

234P Real-world treatment patterns and outcomes of patients receiving palbociclib plus endocrine therapy in Spain: Subgroup analysis based on age, sites and number of metastatic locations, menopausal status and dose received from PALBOSPAIN study by Anton, F. Moreno, Bellet-Ezquerra, M., Sanchez, L.M. Manso, Carrasco, F. Henao, Torres, A. Anton, Morales, S., Ortega, P. Tolosa, Gil, V.L. Obadia, Sampedro, T., Conejero, R. Andrés, Calvo-Martinez, L., Galve-Calvo, E., López, R., Ayala de la Pena, F., Lopez-Tarruella Cobo, S., Hernando Fernandez, B.A., Ruiz, L. Boronat, Cardenas, T. Martos, Chacon, J.I., Jañez, N. Martinez

Get full text

275P Serological response to COVID-19 vaccine in patients with advanced breast cancer by Cuesta, P. Casado, Díaz, F. Pikabea, Galve-Calvo, E., Zumarraga, A., Penas, A. Bilbao, De San Vicente, B. López, Bejarano, C. Figaredo, Pina, I. Bernat, Legaspi, J., Galíndez, J.R. Barceló, Sardina, L. Sande, NuÑo Escolastico, M., Abad Villar, M.T., Lopez, M., Pérez Hoyos, M.T., Sala Gonzalez, M.A., Francés, M. Temiño, Jaramillo, P.L. Loaiza, Díaz de Tuesta del Arco, J.L., Martinez del Prado, P.

Get full text

TEMPORARY REMOVAL: PO-14: Real-world data: incidence of venous thromboembolism recurrence and bleeding among cancer patients by Silva-Cardenas, D C, Pikabea-Diaz, F, Zumarraga-Cuesta, A, Lopez-Santillan, M, Figaredo-Berjano, C, Loaiza-Jaramillo, P L, Casado-Cuesta, P, Temiño-Frances, M, Lopez-de-San-Vicente-Hernandez, B, Novo-Sukia, E, Legaspi-Folgueira, J, Barcelo-Galindez, J R, Sande-Sardina, L, Nuno-Escolastico, M, Abad-Villar, M T, Sala-Gonzalez, M A, Galve-Calvo, E, Martinez-Del-Prado, M P

“…The publisher regrets that this article has been temporarily removed. A replacement will appear as soon as possible in which the reason for the removal of the…”
Get full text

Prognostic Factors Influencing the Selection of Bevacizumab Combined With Chemotherapy in Patients With HER2-Negative Metastatic Breast Cancer in Routine Clinical Practice. Oncosur-Avalox: Observational Cross-Sectional Study by Manso, L., Perez-Carrion, R., Chacon Lopez-Muniz, J.I., García Palomo, A., Galve Calvo, E., Llorente, R.M., Casinello, J., Catalán, G., Llorca, C., Grávalos, C.

Get full text

1035PINDUCTION CHEMOTHERAPY (ICT) WITH DOCETAXEL/CISPLATIN/5-FLUOROURACIL (T/P/F) FOLLOWED BY CHEMORADIOTHERAPY WITH CISPLATIN (CRTP) VS BIORADIOTHERAPY WITH CETUXIMAB (RTCX) FOR UNRESECTABLE LOCALLY ADVANCED HEAD & NECK CANCER (ULAHNC): PRELIMINARY RESULTS ON TOXICITY A TTCC GROUP TRIAL by Hitt, R., Mesia, R., Grau, J.J., Rubió, J., Martínez-Trufero, J., Del Barco Morillo, E., Almodóvar Alvarez, C., Taberna-Sanz, M., García-Girón, C., Vazquez, S., Cirauqui, B., Pastor Borgoñón, M., Galve Calvo, E., Juan-Vidal, O., Lopez, R., Martinez-Galan, J., Bastus, R., Berrocal, A., Adansa Klain, J.C., Cruz Hernandez, J.J.

“…Abstract Background: ICT with taxanes regimens has been demonstrate increase overall survival (OS) in the recent metaanalysis (Blanchard JCO 2013) in patients…”
Get full text